Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 22, 2026Redox BiologyOpen Access

Combination treatment with pyridoxamine and empagliflozin in diabetic mice potently suppressed AGEs accumulation, mitigated mitochondrial damage and PANoptosis, and significantly improved cardiac recovery post-MI/R.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does combination treatment with pyridoxamine and empagliflozin improve cardiac recovery and mitigate mitochondrial damage and PANoptosis in diabetic mice with myocardial ischemia/reperfusion injury?

Population

Diabetic mice and cardiomyocytes subjected to hypoxia/reoxygenation or myocardial ischemia/reperfusion injury

Design

Preclinical

Authors

JYJie YangHarbin University of Science and TechnologyJZJ I A N ZhangRHRong Huang

Discussion

Loading...

Member takes

Overview

May caution against unchecked AGEs in diabetic reperfusion; leaves open whether targeting them improves clinical MI/RI outcomes.

Structured PICO

Does combination treatment with pyridoxamine and empagliflozin improve cardiac recovery and mitigate mitochondrial damage and PANoptosis in diabetic mice with myocardial ischemia/reperfusion injury?

P
Population
Diabetic mice and cardiomyocytes subjected to hypoxia/reoxygenation (H/R) or myocardial ischemia/reperfusion injury (MI/RI)
I
Intervention
Combination treatment with pyridoxamine (an AGEs inhibitor) and empagliflozin (an SGLT2 inhibitor)
O
Outcome
Cardiac recovery post-MI/R, mitochondrial damage, and PANoptosissurrogate

Targeting the AGEs-mitochondrial damage-PANoptosis axis with pyridoxamine and empagliflozin represents a promising strategy to alleviate diabetic myocardial ischemia/reperfusion injury.

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/6a0ff420d674f7c03778d303https://doi.org/10.1016/j.redox.2026.104228
View Full Paper
Ask AI
Bookmark
Share